125 related articles for article (PubMed ID: 20873589)
1. [Serum cytokine profiling of prostate cancer and benign prostatic hyperplasia using recombinant antibody microarray].
Zhang L; Sun SK; Shi LX; Zhang X
Zhonghua Nan Ke Xue; 2010 Jul; 16(7):584-8. PubMed ID: 20873589
[TBL] [Abstract][Full Text] [Related]
2. [Differentially expressed genes in prostate cancer and benign prostatic hyperplasia].
Zhang T; Xu Y; Tang H; Liu M; Ren D; Niu Y
Zhonghua Nan Ke Xue; 2004 Dec; 10(12):897-9. PubMed ID: 15638016
[TBL] [Abstract][Full Text] [Related]
3. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profile in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia.
Alonso V; Neves AF; Marangoni K; Faria PC; Freschi AP; Capaneli AC; Meola J; Goulart LR
Cancer Detect Prev; 2009; 32(4):336-7. PubMed ID: 19026495
[TBL] [Abstract][Full Text] [Related]
5. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance].
Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP
Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704
[TBL] [Abstract][Full Text] [Related]
6. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
7. [Expression and its significance of b-FGF in human benign prostatic hyperplasia and prostatic carcinoma tissues].
Wang FL; Wang H; Qin WJ; Wu GJ; Zhang G; Li KN
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Mar; 20(2):203-5. PubMed ID: 15191726
[TBL] [Abstract][Full Text] [Related]
8. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
9. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
[TBL] [Abstract][Full Text] [Related]
10. Serum resistin levels in benign prostate hyperplasia and non-metastatic prostate cancer: possible role in cancer progression.
Housa D; Vernerova Z; Heracek J; Cechak P; Rosova B; Kuncova J; Haluzik M
Neoplasma; 2008; 55(5):442-6. PubMed ID: 18665756
[TBL] [Abstract][Full Text] [Related]
11. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10.
Li Z; Habuchi T; Tsuchiya N; Mitsumori K; Wang L; Ohyama C; Sato K; Kamoto T; Ogawa O; Kato T
Carcinogenesis; 2004 Feb; 25(2):237-40. PubMed ID: 14604900
[TBL] [Abstract][Full Text] [Related]
12. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
Gao ZW; Liu G; Sheng BW
Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
[TBL] [Abstract][Full Text] [Related]
13. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
[TBL] [Abstract][Full Text] [Related]
14. Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel- and lectin-based proteomics analyses.
Jayapalan JJ; Ng KL; Razack AH; Hashim OH
Electrophoresis; 2012 Jul; 33(12):1855-62. PubMed ID: 22740474
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.
Stamey TA; Warrington JA; Caldwell MC; Chen Z; Fan Z; Mahadevappa M; McNeal JE; Nolley R; Zhang Z
J Urol; 2001 Dec; 166(6):2171-7. PubMed ID: 11696729
[TBL] [Abstract][Full Text] [Related]
16. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutation in prostate needle biopsies--comparison with patients follow-up.
Ecke TH; Schlechte HH; Hübsch A; Lenk SV; Schiemenz K; Rudolph BD; Miller K
Anticancer Res; 2007; 27(6B):4143-8. PubMed ID: 18225585
[TBL] [Abstract][Full Text] [Related]
18. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling.
Luo J; Duggan DJ; Chen Y; Sauvageot J; Ewing CM; Bittner ML; Trent JM; Isaacs WB
Cancer Res; 2001 Jun; 61(12):4683-8. PubMed ID: 11406537
[TBL] [Abstract][Full Text] [Related]
19. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.
Pang J; Liu WP; Liu XP; Li LY; Fang YQ; Sun QP; Liu SJ; Li MT; Su ZL; Gao X
J Proteome Res; 2010 Jan; 9(1):216-26. PubMed ID: 19894759
[TBL] [Abstract][Full Text] [Related]
20. Human telomerase reverse transcriptase expression correlates with vascular endothelial growth factor-promoted tumor cell proliferation in prostate cancer.
Tang J; Wang Z; Li X; Li J; Shi H
Artif Cells Blood Substit Immobil Biotechnol; 2008; 36(2):83-93. PubMed ID: 18437586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
